Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Background: Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an inadequate response to standard treatment. Objective: To determine the clinical effectiveness, safety and cost-effectiveness of these b...

Descrizione completa

Dettagli Bibliografici

Autori principali:	M Rodgers, D Epstein, L Bojke, H Yang, D Craig, T Fonseca, L Myers, I Bruce, R Chalmers, S Bujkiewicz, M Lai, N Cooper, K Abrams, D Spiegelhalter, A Sutton, M Sculpher, N Woolacott
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	NIHR Journals Library 2011-02-01
Serie:	Health Technology Assessment
Soggetti:	etanercept infliximab adalimumab psoriatic arthritis systematic review economic evaluation
Accesso online:	https://doi.org/10.3310/hta15100
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!